Oxford BioMedica (OXB: LSE) specialises in the development of novel gene-based therapeutics for the treatment of cancer, neurodegenerative diseases and other disorders with major unmet clinical needs. The development pipeline includes two novel anti-cancer products in clinical trials and a gene therapy treatment for Parkinsons disease, which is in late preclinical studies. This is underpinned by a broad research pipeline and over 70 patent families.
Oxford BioMedicas products use genes as the mediators of a therapeutic effect and/or immune response. The Companys gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patients immune system to mediate a therapeutic effect. The genes are delivered by the Companys highly engineered viruses or cells.
Oxford BioMedica is headquartered in Oxford, UK, and has a fully owned subsidiary, BioMedica Inc, in San Diego, USA. BioMedica Inc is focused on gene-based therapies for neurological diseases and is progressing relations with the FDA for clinical trial development. |
